Knight Therapeutics (TSE:GUD) Releases Quarterly Earnings Results

Knight Therapeutics (TSE:GUD) announced its earnings results on Thursday. The company reported C$0.09 earnings per share for the quarter, FiscalAI reports. Knight Therapeutics had a negative net margin of 0.84% and a negative return on equity of 0.45%. The business had revenue of C$133.20 million for the quarter.

Here are the key takeaways from Knight Therapeutics’ conference call:

• Knight reported record 2025 results with CAD 452 million in revenue, record adjusted EBITDA of CAD 73 million, and CAD 69 million of cash flow from operations, a 24% revenue increase year‑over‑year.
• Acquisitions of the Paladin and Sumitomo portfolios plus 10 launches in 2025 (and at least 10 planned in 2026) added growth products such as Xcopri, Orgovyx and Myfembree, which management says are tracking at or above expectations.
• 2026 guidance calls for CAD 490–510 million of revenue and adjusted EBITDA of about 15% of revenue, but the outlook depends on assumptions (notably no material hyperinflation accounting in Argentina) and could be revised as launches and integrations play out.
• Financial position improved: net cash of ~CAD 27 million at year‑end, debt of CAD 68 million, reduced leverage to under 1x, repayment of half the revolver principal, and ongoing NCIB share repurchases (≈2.3M shares bought since 2025).
• Operating expenses rose materially (sales & marketing and R&D +30%, G&A +26%) to support a larger 50‑product portfolio and launches, and the company recorded a CAD 6.4 million mark‑to‑market loss on financial assets, increasing near‑term execution and profitability risk.

Knight Therapeutics Price Performance

Shares of TSE:GUD traded up C$0.10 during trading on Thursday, reaching C$6.27. The company had a trading volume of 15,803 shares, compared to its average volume of 93,776. The company has a fifty day moving average of C$6.08 and a two-hundred day moving average of C$6.05. The company has a current ratio of 2.62, a quick ratio of 1.79 and a debt-to-equity ratio of 13.86. The stock has a market capitalization of C$622.54 million, a P/E ratio of -156.75, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.15. Knight Therapeutics has a 12 month low of C$5.43 and a 12 month high of C$6.57.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.